Explore

Reuters Reuters
Analysis-Obesity battle heats up again as Novo claws way back into race with Lilly

Analysis-Obesity battle heats up again as Novo claws way back into race with Lilly

By Maggie Fick and Bhanvi Satija LONDON, Aug 3 - Novo Nordisk investors have found little cause for optimism during a bruising two-year period of profit warnings, leadership upheaval and a sliding share price as rival Eli Lilly streaked ahead. Now they may have reason for hope.
Reuters Reuters
Novo outlook hike falls flat as Wegovy pill sales fail to impress

Novo outlook hike falls flat as Wegovy pill sales fail to impress

By Stine Jacobsen, Maggie Fick and Bhanvi Satija COPENHAGEN, Aug 4 (Reuters) - Novo Nordisk raised its full-year profit and sales outlook on Tuesday but disappointed investors who focused instead on a narrow sales miss for its new Wegovy pill and a trial setback for its next-generation obesity drug
Reuters Reuters
Novo outlook hike falls flat as high Wegovy pill hopes unmet

Novo outlook hike falls flat as high Wegovy pill hopes unmet

By Stine Jacobsen and Maggie Fick COPENHAGEN, Aug 4 (Reuters) - Novo Nordisk beat second-quarter profit forecasts and raised its full-year outlook on Wednesday, but shares in the drugmaker fell 6% as investors focused on underwhelming sales of its Wegovy weight-loss pill.
Trendline Trendline
SB1 Markets Recommends Buying Novo Nordisk Stock Ahead of Earnings Report

SB1 Markets Recommends Buying Novo Nordisk Stock Ahead of Earnings Report

SB1 Markets Recommends Buying Novo Nordisk Stock Ahead of Earnings Report
Trendline Trendline
Novo Nordisk Raises 2026 Financial Outlook Amid Strong GLP-1 Sales

Novo Nordisk Raises 2026 Financial Outlook Amid Strong GLP-1 Sales

Novo Nordisk Raises 2026 Financial Outlook Amid Strong GLP-1 Sales
Reuters Reuters
Novo Nordisk's Q2 profit beats forecasts, raises outlook

Novo Nordisk's Q2 profit beats forecasts, raises outlook

COPENHAGEN, Aug 4 (Reuters) - Novo Nordisk, the maker of weight-loss drug Wegovy, reported a second-quarter adjusted operating profit above forecasts on Tuesday and raised its full-year profit and sales outlook.
Reuters Reuters
Eli Lilly to offer early access to next-gen obesity drug to some patients

Eli Lilly to offer early access to next-gen obesity drug to some patients

By Sneha S K and Deena Beasley Aug 3 (Reuters) - Eli Lilly said on Monday it would allow a limited number of patients to have early access to its experimental obesity drug, retatrutide, before its U.S. FDA approval.
Trendline Trendline
Eli Lilly's Stock Split Consideration Amid Obesity Drug Success

Eli Lilly's Stock Split Consideration Amid Obesity Drug Success

Eli Lilly's Stock Split Consideration Amid Obesity Drug Success
Reuters Reuters
Amgen second-quarter sales rise 9%, profit tops Street view

Amgen second-quarter sales rise 9%, profit tops Street view

By Deena Beasley Aug 3 (Reuters) - Amgen on Tuesday reported second-quarter sales rose 9%, driven by demand for cholesterol drug Repatha, bone drug Evenity and medications for rare diseases, as the company continues to develop experimental weight-loss drug MariTide.
Trendline Trendline
Eli Lilly Expands Access to Experimental Obesity Drug Retatrutide

Eli Lilly Expands Access to Experimental Obesity Drug Retatrutide

Eli Lilly Expands Access to Experimental Obesity Drug Retatrutide
TheStreet TheStreet
Novo Nordisk shares in hot water after disappointing trial

Novo Nordisk shares in hot water after disappointing trial

Investors who had hopes that Novo Nordisk (NVO) could succeed outside of weight-loss drugs were disappointed on Friday, July 31. The Danish drugmaker said its experimental heart drug Ziltivekimab failed the main goal of a large late-stage trial, and the stock fell fast. Novo has spent 2026 trying ...
Rapid Read Rapid Read
Eli Lilly Expands Access to Experimental Obesity Drug Retatrutide

Eli Lilly Expands Access to Experimental Obesity Drug Retatrutide

Eli Lilly has announced that it will allow more patients to apply for special access to retatrutide, an unapproved obesity drug, following requests from doctors. This decision comes after the company granted a single patient access to the drug, prompting inquiries from healthcare providers. Lilly's move marks a shift in its approach to the drug's availability, aligning with FDA guidance for expanded access to investigational treatments.